GCM
UTHR icon

Genus Capital Management’s United Therapeutics UTHR Stock Holding History

Genus Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,560
Closed -$1.26M – 356
2024
Q4 		$1.26M Buy
+3,560
New +$1.31M 0.17% 122

Other funds holding UTHR

AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Genus Capital Management's UTHR Position: Q2 2026 in Review

Genus Capital Management increased its United Therapeutics (UTHR) stake by 14% in Q2 2026, buying an estimated $693K and bringing the position to 10,115 shares worth $5.48M. The position accounts for 0.54% of the portfolio, ranked #58.

Genus Capital Management first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. 380 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Genus Capital Management held 10,115 shares of United Therapeutics worth $5.48M as of Q2 2026.
  • Genus Capital Management bought 1,230 United Therapeutics shares in Q2 2026, an estimated $693K.
  • United Therapeutics made up 0.54% of Genus Capital Management's portfolio in Q2 2026, its #58 holding.
  • Genus Capital Management first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 380 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Genus Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.